We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock

Delisted

CTIC was delisted on the 23rd of June, 2023.

76 hedge funds and large institutions have $63.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 13

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

23% more capital invested

Capital invested by funds: $52M → $63.7M (+$11.8M)

13% more funds holding

Funds holding: 6776 (+9)

90% less call options, than puts

Call options by funds: $747K | Put options by funds: $7.58M

Holders
76
Holders Change
+9
Holders Change %
+13.43%
% of All Funds
2.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
29
Reduced
13
Closed
9
Calls
$747K
Puts
$7.58M
Net Calls
-$6.83M
Net Calls Change
-$6.56M

CTIC Hedge Fund Activity: Q4 2013 in Review

76 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2013, worth a combined $63.7M — up 23% from $52M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CTIC positions and 9 closed out — a net gain of 9 holders — while 29 added to existing stakes and 13 trimmed.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $3.12M. The largest seller was Perceptive Advisors, cutting an estimated $5.97M.

  • 76 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2013, up from 67 in Q3 2013.
  • Funds reported $63.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2013, up 23% quarter-over-quarter.
  • 18 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2013 and 9 closed out, a net change of +9 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2013 was Oxford Asset Management, an estimated $3.12M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2013 was Perceptive Advisors, an estimated $5.97M sold.

Based on aggregated 13F filings for Q4 2013.